Resolution rule no. 40/2015 of the Brazilian health surveillance agency (ANVISA) has introduced significant amendments to the record of health products by eliminating the previously existing procedures. Health products are categorized into four different risk classes: class I as low risk, class II as medium risk, class III as high risk and class IV products have the highest risk. According to the older rule 2/2011, the registration was mandatory for class III and class IV products only. However, a few exceptional class I and class II devices were also eligible for the mandatory registration, but the new rule states that registration is essential for all products related to all four classes. Moreover, some products related to health cannot be considered as health products such as products used in the assessment, development, manufacturing or preparation of health products, machinery for the manufacture of pills and equipment for making prostheses.
GHI Analysis
The leading source of MedTech market intelligence in Latin America. Verified data and competitor insights across the key markets in the region. At GHI, we turn hospital data into strategic actions. Our insights help healthcare companies expand by providing accurate, up-to-date information on hospital infrastructure in LATAM and Asia.
Related Posts
Análise de GHIAnálise de GHI
6 tendências de crescimento no setor farmacêutico latino-americano
6 tendências de crescimento no setor farmacêutico latino-americano
Números essenciais referentes a mercados específicos e segmentos importantes
GHI Analysisnovembro 29, 2021
Análise de GHI
Mexico’s medical device and equipment market: 8% growth YoY
Mexico’s medical device and equipment market: 8% growth YoY
Albeit Mexico’s currency depreciation in 2015 and 2016, the market for medical equipment, devices and…
GHI Analysismaio 5, 2017
Análise de GHI
The Impact of Radiology and Collaborative Platforms on Treatment Models
The Impact of Radiology and Collaborative Platforms on Treatment Models
Radiology directly impacts on all of patient treatment flow, but it can obstruct this flow…
GHI Analysismaio 11, 2021